Algorae PharmaceuticalsASX:1AI -9.09% Quick Ratio is 18.03 as of Dec. 2025, which is 28% above its 10-year median of 14.11. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Algorae Pharmaceuticals ranks better than 90.4% on this metric.
Algorae Pharmaceuticals has a quick ratio of 18.03. It generally indicates good short-term financial strength.
The historical rank and industry rank for Algorae Pharmaceuticals's Quick Ratio or its related term are showing as below:
ASX:1AI'
s Quick Ratio Range Over the Past 10 Years
Min: 3.33 Med: 14.11 Max: 30.86
Current: 18.03
During the past 13 years, Algorae Pharmaceuticals's highest Quick Ratio was 30.86. The lowest was 3.33. And the median was 14.11.
ASX:1AI's Quick Ratio is ranked better than 90.4% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASX:1AI: 18.03
Algorae Pharmaceuticals (ASX:1AI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Algorae Pharmaceuticals Quick Ratio Related Terms
Algorae Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:1AI vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Algorae Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Algorae Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Algorae Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Algorae Pharmaceuticals's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Algorae Pharmaceuticals (ASX:1AI) has a Quick Ratio of 18.03 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Algorae Pharmaceuticals and its competitors. This is 28% above median its historical median of 14.11. Over the past decade, Algorae Pharmaceuticals' Quick Ratio has ranged from 3.33 to 30.86. According to the industry distribution chart, Algorae Pharmaceuticals ranks #136 out of 1417 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Algorae Pharmaceuticals' Quick Ratio too high?
Algorae Pharmaceuticals' current Quick Ratio of 18.03 is 28% above median its 10-year median of 14.11. Over the past 10 years, this metric has ranged from a low of 3.33 to a high of 30.86. The Biotechnology industry median Quick Ratio is 3.60. Algorae Pharmaceuticals' value of 18.03 is 400.8% above this industry median. Based on the distribution chart, Algorae Pharmaceuticals ranks #136 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Algorae Pharmaceuticals' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #136 out of 1417 companies for Quick Ratio. This places Algorae Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Algorae Pharmaceuticals' value of 18.03 is 400.8% above this benchmark. Historically, Algorae Pharmaceuticals' own Quick Ratio has ranged from 3.33 to 30.86 over the past decade. While the company's 10-year median is 14.11 vs. the industry median of 3.60, Algorae Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Algorae Pharmaceuticals's current Quick Ratio of 18.03 is 400.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Algorae Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Algorae Pharmaceuticals's current Quick Ratio is 18.03, which is 28% above median its own 10-year median of 14.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Quick Ratio of 18.03. The current Quick Ratio is 18.03, which is 28% above median its 10-year median of 14.11 and 400.8% above the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Quick Ratio is 18.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:1AI has been successfully added to your 